Belite Bio (BLTE) Liabilities and Shareholders Equity (2021 - 2026)
Belite Bio (BLTE) posted quarterly Liabilities and Shareholders Equity of $811.3 million for Q1 2026, up 394.07% year-over-year from $164.2 million in Q1 2025, and up 3.94% quarter-over-quarter from $780.6 million in Q4 2025.
Belite Bio (BLTE) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Belite Bio's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $811.3 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 394.07% year-over-year to $811.3 million; the TTM figure through Mar 2026 stood at $2.0 billion (up 268.81% YoY), while the FY2025 annual figure was $780.6 million, up 413.08% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $811.3 million, up from $780.6 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $811.3 million in Q1 2026, with the low at $39.8 million in Q1 2023.
- The 5-year median for Liabilities and Shareholders Equity is $117.1 million (2024), against an average of $212.8 million.
- Peak annual rise in Liabilities and Shareholders Equity reached 413.08% in 2025, while the deepest fall reached 32.07% in 2025.
- Belite Bio's Liabilities and Shareholders Equity stood at $44.3 million in 2022, then jumped by 113.77% to $94.6 million in 2023, then soared by 60.74% to $152.1 million in 2024, then surged by 413.08% to $780.6 million in 2025, then rose by 3.94% to $811.3 million in 2026.
- Business Quant data shows BLTE's Liabilities and Shareholders Equity at $811.3 million in Q1 2026, $780.6 million in Q4 2025, and $282.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Belite Bio | 6.40 Bn | 6.40 Bn | - | 811.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 811.27 Mn |
| Dec 31, 2025 | 780.56 Mn |
| Sep 30, 2025 | 282.39 Mn |
| Jun 30, 2025 | 156.41 Mn |
| Mar 31, 2025 | 164.20 Mn |
| Dec 31, 2024 | 152.13 Mn |
| Sep 30, 2024 | 115.82 Mn |
| Jun 30, 2024 | 118.43 Mn |
| Mar 31, 2024 | 101.15 Mn |
| Dec 31, 2023 | 94.64 Mn |
| Sep 30, 2023 | 57.60 Mn |
| Jun 30, 2023 | 60.70 Mn |
| Mar 31, 2023 | 39.82 Mn |
| Dec 31, 2022 | 44.27 Mn |
| Dec 31, 2021 | 18.35 Mn |